S. Nagel

Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel

Wolfgang Schuette, S. Nagel, Thomas Blankenburg et al. · Journal of Clinical Oncology · 2005 · 181 citations

Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)

Christoph Rochlitz, Andreas Lohri, M. Bacchi et al. · Leukemia · 1999 · 111 citations

Hematological Malignancy, Tumor Biology, Swiss Group +11

Phase II Trial of Gemcitabine/Irinotecan in Refractory or Relapsed Small-Cell Lung Cancer

Wolfgang Schuette, S. Nagel, Stefan Juergens et al. · Clinical Lung Cancer · 2005 · 28 citations

Oncology, Phase Ii Trial, Medicine +7

Clinical Benefit in NSCLC: Advanced-Stage Patients Require Symptom-Improving Palliation. Experiences from the ‘Iressa’ Expanded Access Program

Wolfgang Schuette, S. Nagel, Steffen Schaedlich et al. · Oncology Research and Treatment · 2005 · 17 citations

Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study

Wolfgang Schuette, S. Nagel, Monika Serke et al. · Journal of Clinical Oncology · 2004 · 17 citations

Cancer Management, Weekly Docetaxel, Pharmacotherapy +17